|
Synonyms: ATR258 | compound 15 [PMID: 40555230]
Compound class:
Synthetic organic
Comment: ATR-258 is an orally bioavailable, orthosteric GRK-biased β2-adrenoceptor (β2-AR) agonist [1]. Experimental evidence reveals competitive β1-AR antagonist actions and weak partial β3-AR agonist activity. ATR-258 is intended to optimise β2AR-mediated muscular glucose uptake whilst reducing Gs/cAMP-driven cardiac side effects and β-arrestin-dependent desensitisation.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Motso A, Pelcman B, Kalinovich A, Kahlous NA, Bokhari MH, Dehvari N, Halleskog C, Waara E, de Jong J, Cheesman E et al.. (2025)
GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity. Cell, 188 (19): 5142-5156.e23. [PMID:40555230] |